Compare Angi Inc (ANGI) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Angi Inc vs AstraZeneca plc — how do they compare? Angi Inc trades at $4.5 (market cap $182.30M), while AstraZeneca plc trades at $158.4 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 1361.2× Angi Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Angi Inc pays none. Which is the better fit depends on your goals.
| ANGI | AZN | |
|---|---|---|
Market Cap | $182.30M | $248.14B |
Sector | Media | Health |
52-Week High | $18.46 | $209.48 |
52-Week Low | $4.49 | $147.06 |
Enterprise Value | $392.07M | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $4.315, down 5.99% in the last session, reflecting ongoing operational challenges. The stock shows bearish technical signals with support near $4.00 and resistance at $5.00. Recent Q2 2026 earnings missed expectations with a significant EPS loss of $5.70, while revenue declined 11% year-over-year. Despite a low P/E of 14.81 and P/S of 0.19, negative net income margin of -22.35% and ROE of -26.25% highlight profitability struggles. Analyst consensus remains mixed with a $7.00 price target but accelerating pro user churn and legal investigations cloud the outlook.
The outlook for ANGI is cautious due to declining revenue, persistent losses, and competitive pressures. Investment opportunity exists if the company successfully executes its AI pivot and stabilizes user engagement, but risks include ongoing legal probes, high debt, and market share erosion. Near-term volatility is likely amid weak fundamentals and negative sentiment.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
